BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III;
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Newsable Asianet News on MSN1d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement BuildsBridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback